Irvine, CA – According to filings with the U.S. Securities and Exchange Commission, Novus Therapeutics is raising $108,144,151.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Gros played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Novus Therapeutics

We are passionate people driven by a common vision to solve unmet clinical needs for patients in an underserved therapeutic area.  Our product development experience and industry expertise provide the foundation for nimble and creative approaches to bringing new therapies to market. We aspire to deliver novel or significantly improved treatment options to patients in need.

To learn more about Novus Therapeutics, visit http://novustherapeutics.com/

Contact:
David Gros, Chief Executive Officer
949-238-8090
https://www.linkedin.com/in/dagros/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved